The stock price of Oncolytics Biotech, Inc (NASDAQ: ONCY) has plunged by -4.54 when compared to previous closing price of 0.42, but the company has seen a -19.67% decline in its stock price over the last five trading sessions. seekingalpha.com reported 2025-05-14 that Oncolytics Biotech Inc. (NASDAQ:ONCY ) Q1 2025 Results Conference Call May 14, 2025 4:30 PM ET Company Participants Jon Patton – Director of Investor Relations and Communications Wayne Pisano – Chair of Oncolytics’ Board of Directors and Interim Chief Executive Officer Dr. Tom Heineman – Chief Medical Officer Christophe Degois – Vice President of Business Development Kirk Look – Chief Financial Officer Conference Call Participants Patrick Trucchio – H.C. Wainwright Michael Freeman – Raymond James Operator Good afternoon, and welcome to Oncolytics Biotech First Quarter Conference Call.
Is It Worth Investing in Oncolytics Biotech, Inc (NASDAQ: ONCY) Right Now?
Company’s 36-month beta value is 0.79.Analysts have differing opinions on the stock, with 2 analysts rating it as a “buy,” 5 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for ONCY is 84.85M, and currently, short sellers hold a 2.63% ratio of that floaft. The average trading volume of ONCY on May 23, 2025 was 316.57K shares.
ONCY’s Market Performance
ONCY’s stock has seen a -19.67% decrease for the week, with a -29.07% drop in the past month and a -44.61% fall in the past quarter. The volatility ratio for the week is 1.35%, and the volatility levels for the past 30 days are at 3.41% for Oncolytics Biotech, Inc The simple moving average for the last 20 days is -21.78% for ONCY stock, with a simple moving average of -51.92% for the last 200 days.
Analysts’ Opinion of ONCY
Many brokerage firms have already submitted their reports for ONCY stocks, with Maxim Group repeating the rating for ONCY by listing it as a “Buy.” The predicted price for ONCY in the upcoming period, according to Maxim Group is $3 based on the research report published on October 06, 2022 of the previous year 2022.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see ONCY reach a price target of $15. The rating they have provided for ONCY stocks is “Buy” according to the report published on February 17th, 2021.
ONCY Trading at -27.24% from the 50-Day Moving Average
After a stumble in the market that brought ONCY to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -73.73% of loss for the given period.
Volatility was left at 3.41%, however, over the last 30 days, the volatility rate increased by 1.35%, as shares sank -31.10% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -36.21% lower at present.
During the last 5 trading sessions, ONCY fell by -19.67%, which changed the moving average for the period of 200-days by -58.72% in comparison to the 20-day moving average, which settled at $0.5138. In addition, Oncolytics Biotech, Inc saw -56.02% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for ONCY
The total capital return value is set at -1.97. Equity return is now at value -211.24, with -115.29 for asset returns.
Based on Oncolytics Biotech, Inc (ONCY), the company’s capital structure generated 0.15 points at debt to capital in total, while cash flow to debt ratio is standing at -18.94.
Currently, EBITDA for the company is -33.71 million with net debt to EBITDA at 0.43. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.21.
Conclusion
In a nutshell, Oncolytics Biotech, Inc (ONCY) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
